Asahi Kaisei Adr Stock Price, News & Analysis

Asahi Kasei (AHKSY) announced that Nefecon (TARPEYO) is included in the KDIGO 2025 Clinical Practice Guideline for IgA nephropathy (IgAN) and IgA vasculitis. KDIGO recommends a 9-month course of Nefecon for patients at risk of progressive kidney-function loss, citing phase 3 NefIgArd randomized placebo-controlled trial results showing reduced loss of kidney function and reduced proteinuria in adults on stable RAS inhibitor therapy. KDIGO also notes Nefecon is the only approved IgAN therapy shown to reduce pathogenic IgA levels. Adverse events in the trial were described as mild or moderate and generally resolved after treatment stopped.

Asahi Kasei (OTC: AHKSY) announced on October 23, 2025 that it received approval to build new facilities at Kawasaki Works to manufacture electrolysis cell frames and membranes for alkaline water electrolysis (clean hydrogen) and ion-exchange membrane chlor-alkali electrolysis.

The project, initiated on December 18, 2024, was selected for financial support under Japan’s Ministry of Economy, Trade, and Industry GX Supply Chain Development Program. The move aims to strengthen vertical integration, increase production capacity, and support hydrogen, chlorine, and caustic soda markets.

Under its medium-term plan the company classifies these businesses as Growth Potential, and in May 2025 it discontinued several Kawasaki Works resin and latex businesses, designating Kawasaki as a key site for its Energy & Infrastructure operations.

Asahi Kasei (OTC: AHKSY) introduced two new specialty grades in its Sonanos™ next‑generation excipient portfolio: Sonanos PG for sustained release of biologics and peptides and Sonanos DS to improve solubility of poorly water‑soluble APIs. Paid samples are available now, with GMP‑manufactured products planned for 2027 to support clinical development. Since 2020 the company has completed more than 60 feasibility studies using Sonanos samples. A vaccine‑grade variant (Sonanos DV) is already in GMP production via spin‑out DiveRadGel to support early‑stage clinical trials. Sonanos and related excipients will be showcased at AAPS 2025 PharmSci 360 in San Antonio (Nov 10–12), including a Nov 11 technical presentation.

Asahi Kasei (AHKSY) announced U.S. FDA premarket approval for ZOLL’s Zenix® monitor/defibrillator on October 9, 2025, expanding its critical care product lineup.

The Zenix device targets EMS and hospital use, features a large touchscreen, workflow automation, real-time customization, Real BVM Help® and Real CPR Help® technologies, and is available now in the U.S. and Canada. ZOLL has driven material growth for Asahi Kasei’s healthcare sector, cited as a fivefold increase in net sales and a sevenfold rise in operating income since 2012. Management framed the approval as aligned with the company’s medium-term plan to introduce high-value products and sustain long-term profitable growth.

Asahi Kasei Microdevices (OTC:AHKSY) has launched its AK581xAIM Antenna-in-Module (AiM) millimeter wave radar modules for advanced human sensing applications. The new modules enable camera-less detection of vital signs, falls, posture, and position, addressing growing privacy concerns in healthcare monitoring.

The compact 23mm × 23mm modules integrate AK581x mmWave radar IC with a 4-in/4-out antenna array, targeting the aging-in-place market, where 75% of US adults over 50 prefer to stay in their homes. The company is offering two development kits: the AIMEZ-V for rapid proof-of-concept testing and the LUMI for advanced algorithm development, both designed to accelerate market deployment.

Asahi Kasei (OTC:AHKSY) will showcase groundbreaking innovations at K 2025, the world's premier plastics and rubber trade fair in Düsseldorf, Germany from October 8-15, 2025. The company will unveil two major technological breakthroughs: a PFAS-free polyamide and a novel CFRP recycling technology that preserves continuous carbon fiber structure.

Key innovations include a recycling process using electrolyzed sulfuric acid for CFRP pressure vessels, bio-based compounds utilizing cellulose nano fiber (CNF), and advanced automotive solutions featuring AZP™ transparent polymer for head-up displays, SEBS materials for streamlined interior production, and mPPE solutions for radar applications and thermal management.

Asahi Kasei (AHKSY) has successfully implemented its chlor-alkali electrolysis technology at Bondalti Chemicals' new facility in Estarreja, Portugal. The state-of-the-art plant features nine chlor-alkali electrolyzers, with one dedicated to trial runs testing new components for enhanced environmental performance.

The modernization project, co-financed by the Portuguese Recovery and Resilience Plan, aims to significantly improve efficiency and support Bondalti's decarbonization goals. The facility utilizes Asahi Kasei's newest ion exchange membranes and electrodes, demonstrating improved performance compared to conventional products. The project represents a collaboration between Asahi Kasei, CAC Engineering, and Bondalti, combining technological innovation with operational excellence.

Asahi Kasei (OTC:AHKSY) has announced plans to double its PIMEL™ photosensitive polyimide (PSPI) production capacity at its Fuji City facility in Japan by 2030. The company will invest ¥16 billion in this expansion to meet growing semiconductor industry demand, which is projected to grow at an 8% annual rate.

PIMEL™ is a crucial material used in semiconductor manufacturing for buffer coatings, passivation layers, and redistribution layers. The expansion follows the completion of a new plant in December 2024 and aligns with Asahi Kasei's "Trailblaze Together" medium-term management plan, positioning its electronics business as a "First Priority" growth driver.

Bionova Scientific, a subsidiary of Asahi Kasei (OTC:AHKSY), has opened a new 10,000 square-foot plasmid DNA (pDNA) facility in The Woodlands, Texas. The state-of-the-art facility will develop and manufacture research-grade pDNA materials for cell and gene therapy applications.

The strategic expansion aims to support the growing biopharmaceutical industry, with the global pharmaceutical market expected to reach $3 trillion by 2033. The facility will begin offering clinical to commercial-scale CGMP production of pDNA by Q4 2025, complementing Bionova's existing antibody and protein CDMO services in the San Francisco Bay Area.

This expansion represents a core growth initiative within Asahi Kasei's Life Science group, positioning Bionova to serve the rapidly expanding cell and gene therapy ecosystem in the United States.